Dermatology · San Francisco, CA
NPI
1144483124
Since 2008
Specialty
Dermatology
Code 207N00000X
Group practices
3
Medicare group memberships
Hospitals
0
Hospital affiliations
595 Buckingham Way Ste 220
San Francisco, CA, 94132
Phone (415) 333-0348
Groups this clinician bills Medicare through
Medicare paid, 2024
$285K
3,826 services
Medicare patients, 2024
679
Average age 76
Drug cost, 2024
$2.4M
1,521 prescriptions
Company payments, 2025
$596K
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tina Bhutani-Jacques was code 17003 (destruction skin lesion), 1,007 times for 140 patients. In total Tina Bhutani-Jacques billed 3,826 services in 59 codes, and Medicare paid $285K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-02-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,007 | 140 | $6.42 | $6,469 |
| 96910 Skin | Office | 882 | 27 | $101.18 | $89K |
| 99213 Office E&M - Established | Office | 499 | 343 | $81.42 | $41K |
| 99214 Office E&M - Established | Office | 339 | 259 | $109.44 | $37K |
| 17000 Destruction Skin Lesion | Office | 218 | 169 | $57.30 | $12K |
| 17004 Destruction Skin Lesion | Office | 139 | 85 | $166.46 | $23K |
| 11102 Skin Biopsy | Office | 138 | 118 | $90.58 | $12K |
| 17110 Destruction Skin Lesion | Office | 130 | 100 | $107.26 | $14K |
| 99203 Office E&M - New | Office | 80 | 80 | $96.57 | $7,726 |
| 99204 Office E&M - New | Office | 67 | 67 | $146.32 | $9,803 |
| 99212 Office E&M - Established | Office | 57 | 55 | $54.48 | $3,105 |
| 11103 Skin Biopsy | Office | 28 | 22 | $44.82 | $1,255 |
| 11104 Skin Biopsy | Office | 24 | 20 | $129.69 | $3,113 |
| 99202 Office E&M - New | Office | 18 | 18 | $66.47 | $1,196 |
By year: 2022 $44K for 957 services; 2023 $35K for 795 services; 2024 $285K for 3,826 services.
Medicare prescription drug claims, 2024
In 2024, the drug Tina Bhutani-Jacques prescribed most often to Medicare patients was Triamcinolone Acetonide, with 233 prescriptions and refills. In total Tina Bhutani-Jacques wrote 1,521 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 233 | 297 | 126 | $3,530 |
| Clobetasol Propionate Generic | 176 | 185 | 85 | $7,344 |
| Ketoconazole Generic | 124 | 143 | 59 | $2,272 |
| Fluocinonide Generic | 62 | 66 | 32 | $1,943 |
| Desonide Generic | 60 | 70 | 33 | $4,092 |
| Dupixent Pen Dupilumab | 51 | 59 | Under 11 | $220K |
| Taltz Autoinjector Ixekizumab | 51 | 55 | Under 11 | $368K |
| Halobetasol Propionate Generic | 46 | 63 | 16 | $3,085 |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 45 | 49 | 27 | $1,571 |
| Metronidazole Generic | 44 | 54 | 22 | $1,948 |
| Hydrocortisone Generic | 39 | 40 | 17 | $220 |
| Skyrizi Pen Risankizumab-Rzaa | 29 | 73 | 12 | $581K |
| Ciclopirox Generic | 28 | 29 | 15 | $716 |
| Acitretin Generic | 26 | 26 | Under 11 | $15K |
| Tacrolimus Generic | 26 | 35 | 14 | $3,113 |
Brand drugs: 335 claims; generic drugs: 1,186 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tina Bhutani-Jacques $596K ($596K in general payments such as food, travel and fees) from 24 companies. The largest payer was Janssen Biotech, Inc. with $101K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 99 | $101K |
| Genzyme Corporation SNY | 48 | $87K |
| Arcutis Biotherapeutics, Inc. ARQT | 71 | $74K |
| Lilly USA, LLC LLY | 71 | $72K |
| Abbvie Inc. ABBV | 73 | $58K |
| Galderma Laboratories, L.P. GALD.SW | 64 | $52K |
| Organon LLC OGN | 40 | $43K |
| UCB, Inc. UCB.BR | 36 | $27K |
| E.R. Squibb & Sons, L.L.C. BMY | 15 | $20K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 5 | $13K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.